Heidi H Gillenwater

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi request reprint A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer
    Heidi H Gillenwater
    Department of Hematology Oncology, University of Virginia Health Services, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Lung Cancer 47:413-9. 2005
  2. ncbi request reprint A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
  3. pmc Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
  4. pmc Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer
    David R Jones
    Department of Surgery, University of Virginia, Charlottesville, VA, USA
    J Thorac Oncol 7:1683-90. 2012
  5. ncbi request reprint Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 95:1520-7. 2002
  6. ncbi request reprint Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
    Stacy S Shord
    School of Pharmacy, CB 7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Chemother Pharmacol 51:328-36. 2003
  7. ncbi request reprint Treatment options for small cell lung cancer
    Todd Wolf
    Division of Hematology and Oncology, University of Virginia, Box 800716, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Curr Oncol Rep 6:268-71. 2004
  8. ncbi request reprint Second-line treatment of small-cell lung cancer
    Cecilia MacCallum
    Division of Hematology and Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Curr Oncol Rep 8:258-64. 2006
  9. doi request reprint Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion
    David R Jones
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908 0679, USA
    J Thorac Oncol 5:75-81. 2010
  10. pmc Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    Gary M Strauss
    Tufts Medical Center, Division of Medical Oncology, Tufts NEMC, Boston, MA 02111, USA
    J Clin Oncol 26:5043-51. 2008

Detail Information

Publications11

  1. ncbi request reprint A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer
    Heidi H Gillenwater
    Department of Hematology Oncology, University of Virginia Health Services, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Lung Cancer 47:413-9. 2005
    ....
  2. ncbi request reprint A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  3. pmc Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  4. pmc Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer
    David R Jones
    Department of Surgery, University of Virginia, Charlottesville, VA, USA
    J Thorac Oncol 7:1683-90. 2012
    ..On the basis of prior preclinical evaluations, we hypothesized that combined induction proteasome and histone deacetylase inhibitor therapy, followed by tumor resection, is feasible...
  5. ncbi request reprint Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 95:1520-7. 2002
    ..This Phase II multicenter, open-label, single-arm study evaluated the efficacy and safety of a three-drug combination of irinotecan (CPT-11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC)...
  6. ncbi request reprint Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
    Stacy S Shord
    School of Pharmacy, CB 7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Chemother Pharmacol 51:328-36. 2003
    ..We designed this pharmacokinetic study to assess the ability of a fixed dose rate of gemcitabine to achieve the desired steady-state concentration in the absence and presence of paclitaxel in patients with solid tumors...
  7. ncbi request reprint Treatment options for small cell lung cancer
    Todd Wolf
    Division of Hematology and Oncology, University of Virginia, Box 800716, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Curr Oncol Rep 6:268-71. 2004
    ..This trial may change the standard of care for patients with extensive-stage disease. A similar ongoing trial in the United States is attempting to confirm these results...
  8. ncbi request reprint Second-line treatment of small-cell lung cancer
    Cecilia MacCallum
    Division of Hematology and Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Curr Oncol Rep 8:258-64. 2006
    ..Combination therapies have also been investigated, and some have been shown to increase activity over single agents, but toxicity and quality of life variables are imperative in the treatment of this patient population...
  9. doi request reprint Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion
    David R Jones
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908 0679, USA
    J Thorac Oncol 5:75-81. 2010
    ..This dose escalation phase I study was designed to determine the maximum tolerated dose of intrapleural docetaxel administered through an implantable catheter in subjects with MPE...
  10. pmc Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    Gary M Strauss
    Tufts Medical Center, Division of Medical Oncology, Tufts NEMC, Boston, MA 02111, USA
    J Clin Oncol 26:5043-51. 2008
    ..This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC...
  11. ncbi request reprint Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
    Thomas A Hensing
    Kellogg Cancer Center, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Anticancer Drugs 17:697-704. 2006
    ..The lack of activity in either patient subgroup, however, does not support further evaluation of this drug as a single agent in this disease...